{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:35:54Z","timestamp":1793219754161,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.09.013","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:22:15Z","timestamp":1790292135000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lipoprotein(a) management simplified: The National Lipid Association lipid simplified series"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2643-2288","authenticated-orcid":false,"given":"Marlys L.","family":"Koschinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-1730","authenticated-orcid":false,"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jacl.2026.09.013_bib1","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"39","key":"10.1016\/j.jacl.2026.09.013_bib2","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacl.2026.09.013_bib3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0000000000001016","article-title":"Evolving guidelines on lipoprotein(a)","volume":"36","author":"Boffa","year":"2025","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2026.09.013_bib4","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.013_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41569-026-01278-8","article-title":"Addressing the Lp(a) hypothesis: will lowering Lp(a) decrease the risk of cardiovascular events?","volume":"23","author":"Koschinsky","year":"2026","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.013_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-med-050124-025051","article-title":"Lipoprotein(a): an underappreciated inherited risk factor for atherosclerosis, aortic stenosis, and abdominal aortic aneurysm","volume":"77","author":"Koschinsky","year":"2026","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.013_bib7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"18","key":"10.1016\/j.jacl.2026.09.013_bib8","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/eurjpc\/zwaa063","article-title":"Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions","volume":"28","author":"Welsh","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"44","key":"10.1016\/j.jacl.2026.09.013_bib9","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US family heart database","volume":"46","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.09.013_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.013_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2026.102601","article-title":"Intraindividual Lp(a)-variability in a real-world setting","volume":"5","author":"Seidel","year":"2026","journal-title":"JACC Adv"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.013_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeae064","article-title":"Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk","volume":"4","author":"Harb","year":"2024","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.jacl.2026.09.013_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.013_bib14","first-page":"1208","article-title":"Pelacarsen: mechanism of action and Lp(a)-lowering effect","volume":"19","author":"Bhatia","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"24","key":"10.1016\/j.jacl.2026.09.013_bib15","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.013_bib16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.09.013_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2022.04.020","article-title":"Existing and emerging strategies to lower lipoprotein(a)","volume":"349","author":"Schwartz","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.09.013_bib18","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein(a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2026.09.013_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119189","article-title":"Why has the \"Lp(a) receptor\" proven so elusive?","volume":"404","author":"Lambert","year":"2025","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.jacl.2026.09.013_bib20","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.jacl.2026.09.013_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"44","key":"10.1016\/j.jacl.2026.09.013_bib22","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jacl.2026.09.013_bib23","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jacl.2026.09.013_bib24","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with Low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.013_bib25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","year":"2014","journal-title":"New Engl J Med"},{"issue":"14","key":"10.1016\/j.jacl.2026.09.013_bib26","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.013_bib27","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033562","article-title":"Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): the Multi-Ethnic Study of Atherosclerosis","volume":"13","author":"Bhatia","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2026.09.013_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100674","article-title":"Aspirin use for primary prevention among US adults with and without elevated lipoprotein(a)","volume":"18","author":"Razavi","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.013_bib29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jacl.2026.09.013_bib30","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jacl.2026.09.013_bib31","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran - a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.013_bib32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.013_bib33","first-page":"737","article-title":"Multidisciplinary teams in clinical lipidology and cardiometabolic care: a National Lipid Association expert clinical review","volume":"19","author":"Cheeley","year":"2025","journal-title":"J Clin Lipidol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:53:48Z","timestamp":1791960828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426005246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"alternative-id":["S1933287426005246"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.013","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) management simplified: The National Lipid Association lipid simplified series","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}